Site-directed mutations in the lanthipeptide mutacin 1140

Applied and Environmental Microbiology

Volumn 79, Issue 13, 2013, Pages 4015-4023

  Chen, Shaorong ^a   Wilson Stanford, Shawanda ^a   Cromwell, William ^a   Hillman, Jeffrey D ^b   Guerrero, Adam ^a   Allen, Charlotte A ^a   Sorg, Joseph A ^a   Smith, Leif ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

^b Oragenics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-MICROBIAL ACTIVITY; CLOSTRIDIUM DIFFICILE; MUTAGENESIS EXPERIMENT; SITE DIRECTED MUTAGENESIS; SITE-DIRECTED MUTATION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS MUTANS; STREPTOCOCCUS PNEUMONIAE;

ANTIBIOTICS; BACTERIA; MUTAGENESIS;

BIOASSAY;

BACTERIOCIN; MUTACIN 1140; PEPTIDE;

ANTIBIOTICS; ANTIMICROBIAL ACTIVITY; BACTERIUM; BIOACTIVITY; BIOASSAY; EXPERIMENTAL STUDY; MUTATION; PEPTIDE; PHYSIOLOGY;

ARTICLE; BIOTECHNOLOGY; CHEMICAL STRUCTURE; CLOSTRIDIUM DIFFICILE; DRUG EFFECT; GENE VECTOR; GENETICS; ISOLATION AND PURIFICATION; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; MICROCOCCUS LUTEUS; SITE DIRECTED MUTAGENESIS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS MUTANS; SUICIDE TRANSGENE;

BACTERIOCINS; BIOTECHNOLOGY; CLOSTRIDIUM DIFFICILE; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; MICROCOCCUS LUTEUS; MOLECULAR STRUCTURE; MUTAGENESIS, SITE-DIRECTED; PEPTIDES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS MUTANS;

BACTERIA (MICROORGANISMS); CLOSTRIDIUM DIFFICILE; MICROCOCCUS LUTEUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS MUTANS; STREPTOCOCCUS PNEUMONIAE;

EID: 84879800778     PISSN: 00992240     EISSN: 10985336     Source Type: Journal    
DOI: 10.1128/AEM.00704-13     Document Type: Article

References (43)

1. Arnison PG, Bibb MJ, Bierbaum G, Bowers AA, Bugni TS, Bulaj G, Camarero JA, Campopiano DJ, Challis GL, Clardy J, Cotter PD, Craik DJ, Dawson M, Dittmann E, Donadio S, Dorrestein PC, Entian K-D, Fischbach MA, Garavelli JS, Göransson U, Gruber CW, Haft DH, Hemscheidt TK, Hertweck C, Hill C, Horswill AR, Jaspars M, Kelly WL, Klinman JP, Kuipers OP, Link AJ, Liu W, Marahiel MA, Mitchell DA, Moll GN, Moore BS, Müller R, Nair SK, Nes IF, Norris GE, Olivera BM, Onaka H, Patchett ML, Piel J, Reaney MJT, Rebuffat S, Ross RP, Sahl Schmidt H-GEW, Selsted ME, Severinov K, Shen B, Sivonen K, Smith L, Stein T, Süssmuth RD, Tagg JR, Tang G-L, Truman AW, Vederas JC, Walsh CT, Walton JD, Wenzel SC, Willey JM, van der Donk WA. 2013. Ribosomally synthesized and post-translationally modified peptide natural products: overview and recommendations for a universal nomenclature. Nat. Prod. Rep. 30:108-160.
2. Kodani S, Hudson ME, Durrant MC, Buttner MJ, Nodwell JR, Willey JM. 2004. The SapB morphogen is a lantibiotic-like peptide derived from the product of the developmental gene ramS in Streptomyces coelicolor. Proc. Natl. Acad. Sci. U. S. A. 101:11448-11453.
3. Bierbaum G, Sahl HG. 2009. Lantibiotics: mode of action, biosynthesis and bioengineering. Curr. Pharm. Biotechnol. 10:2-18.
4. Nagao J-I, Nishie M, Sonomoto K. 2011. Methodologies and strategies for the bioengineering of lantibiotics. Curr. Pharm. Biotechnol. 12:1221-1230.
5. Smith L, Hillman JD. 2008. Therapeutic potential of type A (I) lantibiotics, a group of cationic peptide antibiotics. Curr. Opin. Microbiol. 11: 401-408.
6. Wilson-Stanford S, Smith L. 2011. Commercial development and application of type A lantibiotics. Recent Pat. Antiinfect. Drug Discov. 6:175-185.
7. Bierbaum G, Sahl HG. 1993. Lantibiotics-unusually modified bacteriocin-like peptides from Gram-positive bacteria. Zentralbl. Bakteriol. 278: 1-22.
8. Chatterjee C, Xie PML, van der Donk W. 2005. Biosynthesis and mode of action of lantibiotics. Chem. Rev. 105:633-683.
9. Smith L, Novak J, Rocca J, McClung S, Hillman JD, Edison AS. 2000. Covalent structure of mutacin 1140 and a novel method for the rapid identification of lantibiotics. Eur. J. Biochem. 267:6810-6816.
10. Breukink E, van Heusden HE, Vollmerhaus PJ, Swiezewska E, Brunner L, Walker S, Heck AJR, de Kruijff B. 2003. Lipid II is an intrinsic component of the pore induced by nisin in bacterial membranes. J. Biol. Chem. 278:19898-19903.
11. Hasper HE, Kramer NE, Smith JL, Hillman JD, Zachariah C, Kuipers OP, de Kruijff B, Breukink E. 2006. An alternative bactericidal mechanism of action for lantibiotic peptides that target lipid II. Science 313: 1636-1637.
12. Smith L, Hasper H, Breukink E, Novak J, Cerkasov J, Hillman JD, Wilson-Stanford S, Orugunty RS. 2008. Elucidation of the antimicrobial mechanism of mutacin 1140. Biochemistry 47:3308-3314.
13. Wilson-Stanford S, Kalli A, Hakansson K, Kastrantas J, Orugunty RS, Smith L. 2009. Oxidation of lanthionines renders the lantibiotic nisin inactive. Appl. Environ. Microbiol. 75:1381-1387.
14. Hsu STD, Breukink E, Tischenko E, Lutters MAG, de Kruijff B, Kaptein R, Bonvin A, van Nuland NAJ. 2004. The nisin-lipid II complex reveals a pyrophosphate cage that provides a blueprint for novel antibiotics. Nat. Struct. Mol. Biol. 11:963-967.
15. Hillman JD. 2001. Replacement therapy of dental caries. Oper. Dent. 6(Suppl):39-49.
16. Hillman JD. 2002. Genetically modified Streptococcus mutans for the prevention of dental caries. Antonie Van Leeuwenhoek 82:361-366.
17. Hillman JD, Brooks TA, Michalek SM, Harmon CC, Snoep JL, van der Weijden CC. 2000. Construction and characterization of an effector strain of Streptococcus mutans for replacement therapy of dental caries. Infect. Immun. 68:543-549.
18. Ghobrial O, Derendorf H, Hillman JD. 2010. Pharmacokinetic and pharmacodynamic evaluation of the lantibiotic MU1140. J. Pharm. Sci. 99:2521-2528.
19. Ghobrial OG, Derendorf H, Hillman JD. 2009. Pharmacodynamic activity of the lantibiotic MU1140. Int. J. Antimicrob. Agents 33:70-74.
20. Smith L, Zachariah C, Thirumoorthy R, Rocca J, Novak J, Hillman JD, Edison AS. 2003. Structure and dynamics of the lantibiotic mutacin 1140. Biochemistry 42:10372-10384.
21. Hillman JD, Johnson KP, Yaphe BI. 1984. Isolation of a Streptococcus mutans strain producing a novel bacteriocin. Infect. Immun. 44:141-144.
22. Hillman JD, Johnson KP, Yaphe BI. 1983. Characterization of a Streptococcus mutans bacteriocin with novel properties. J. Dent. Res. 62:241-241.
23. Field D, Connor PMO, Cotter PD, Hill C, Ross RP. 2008. The generation of nisin variants with enhanced activity against specific Grampositive pathogens. Mol. Microbiol. 69:218-230.
24. Rink R, Wierenga J, Kuipers A, Muskens LD, Driessen AJM, Kuipers OP, Moll GN. 2007. Production of dehydroamino acid-containing peptides by Lactococcus lactis. Appl. Environ. Microbiol. 73:1792-1796.
25. Bonelli RR, Schneider T, Sahl HG, Wiedemann I. 2006. Insights into in vivo activities of lantibiotics from gallidermin and epidermin mode-ofaction studies. Antimicrob. Agents Chemother. 50:1449-1457.
26. Ottenwalder B, Kupke T, Brecht S, Gnau V, Metzger J, Jung G, Gotz F. 1995. Isolation and characterization of genetically-engineered gallidermin and epidermin analogs. Appl. Environ. Microbiol. 61:3894-3903.
27. Macrina FL, Evans RP, Tobian JA, Hartley DL, Clewell DB, Jones KR. 1983. Novel shuttle plasmid vehicles for Escherichia-Streptococcus transgeneric cloning. Gene 25:145-150.
28. Perry D, Nilsen LJ, Kuramitsu HK. 1985. Mapping of a cloned glucosyltransferase gene in Streptococcus mutans. Infect. Immun. 50:130-135.
29. Li Y-H, Tang N, Aspiras MB, Lau PCY, Lee JH, Ellen RP, Cvitkovitch DG. 2002. A quorum-sensing signaling system essential for genetic competence in Streptococcus mutans is involved in biofilm formation. J. Bacteriol. 184:2699-2708.
30. Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-eighth edition. CLSI document M07-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
31. Hillman JD, Novak J, Sagura E, Gutierrez JA, Brooks TA, Crowley PJ, Hess M, Azizi A, Leung KP, Cvitkovitch D, Bleiweis AS. 1998. Genetic and biochemical analysis of mutacin 1140, a lantibiotic from Streptococcus mutans. Infect. Immun. 66:2743-2749.
32. Qi FX, Chen P, Caufield PW. 1999. Purification of mutacin III from group III Streptococcus mutans UA787 and genetic analyses of mutacin III biosynthesis genes. Appl. Environ. Microbiol. 65:3880-3887.
33. Chaney N, Wilson-Stanford S, Kastrantas J, Dahal N, Smith L. 2009. Rapid method for extracting the antibiotic mutacin 1140 from complex fermentation medium yeast extract. Can. J. Microbiol. 55:1261-1266.
34. Dahal N, Chaney N, Ellis D, Lu S-E, Smith L. 2010. Optimization of the production of the lantibiotic mutacin 1140 in modifiedM9media. Process Biochem. 5:1187-1191.
35. Siezen RJ, Leunissen JA. 1997. Subtilases: the superfamily of subtilisinlike serine proteases. Protein Sci. 6:501-523.
36. Chan WC, Dodd HM, Horn N, Maclean K, Lian LY, Bycroft BW, Gasson MJ, Roberts GCK. 1996. Structure-activity relationships in the peptide antibiotic nisin: role of dehydroalanine 5. Appl. Environ. Microbiol. 62:2966-2969.
37. Killian JA, Salemink I, dePlanque MRR, Lindblom G, Koeppe RE, II, Greathouse DV. 1996. Induction of nonbilayer structures in diacylphosphatidylcholine model membranes by transmembrane alpha-helical peptides: importance of hydrophobic mismatch and proposed role of tryptophans. Biochemistry 35:1037-1045.
38. Choma C, Gratkowski H, Lear JD, DeGrado WF. 2000. Asparaginemediated self-association of a model transmembrane helix. Nat. Struct. Biol. 7:161-166.
39. Zhou FX, Merianos HJ, Brunger AT, Engelman DM. 2001. Polar residues drive association of polyleucine transmembrane helices. Proc. Natl. Acad. Sci. U. S. A. 98:2250-2255.
40. Kupke T, Kempter C, Jung G, Gotz F. 1995. Oxidative decarboxylation of peptides catalyzed by flavoprotein EpiD-determination of substrate specificity using peptide libraries and neutral loss mass spectrometry. J. Biol. Chem. 270:11282-11289.
41. Killgore G, Thompson A, Johnson S, Brazier J, Kuijper E, Pepin J, Frost EH, Savelkoul P, Nicholson B, van den Berg RJ, Kato H, Sambol SP, Zukowski W, Woods C, Limbago B, Gerding DN, McDonald LC. 2008. Comparison of seven techniques for typing international epidemic strains of Clostridium difficile: restriction endonuclease analysis, pulsed-field gel electrophoresis, PCR-ribotyping, multilocus sequence typing, multilocus variable-number tandem-repeat analysis, amplified fragment length polymorphism, and surface layer protein A gene sequence typing. J. Clin. Microbiol. 46:431-437.
42. Sorg JA, Sonenshein AL. 2010. Inhibiting the initiation of Clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid. J. Bacteriol. 192:4983-4990.
43. Ajdić D, McShan WM, McLaughlin RE, Savić G, Chang J, Carson MB, Primeaux C, Tian R, Kenton S, Jia H, Lin S, Qian Y, Li S, Zhu H, Najar F, Lai H, White J, Roe BA, Ferretti JJ. 2002. Genome sequence of Streptococcus mutans UA159, a cariogenic dental pathogen. Proc. Natl. Acad. Sci. U. S. A. 99:14434-14439.